Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 28, 2013; 19(44): 7955-7971
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.7955
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.7955
Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
Inês Marques, Ramon Andrade de Mello, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
António Araújo, Ramon Andrade de Mello, Department of Medical Oncology, Portuguese Oncology Institute, 4200-072 Porto, Portugal
Inês Marques, Molecular Oncology Group, Research Center, Portuguese Oncology Institute, 4200-072 Porto, Portugal
Ramon Andrade de Mello, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom
Author contributions: All authors contributed equally to the manuscript preparation.
Correspondence to: Ramon Andrade de Mello, MD, PhD, Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ramondemello@gmail.com
Telephone: +351-225-084000 Fax: +351-225-084010
Received: June 30, 2013
Revised: September 19, 2013
Accepted: October 19, 2013
Published online: November 28, 2013
Revised: September 19, 2013
Accepted: October 19, 2013
Published online: November 28, 2013
Core Tip
Core tip: Metastatic colorectal cancer is a very aggressive disease. However, recently developed chemotherapeutic protocols and targeted drugs have emerged as a valuable tool for treating this set of patients. Our manuscript brings the readers current trends and future perspectives in this field.